8-K: Ensysce Biosciences Faces Nasdaq Delisting Hurdles

Ensysce Biosciences received notices from Nasdaq regarding compliance with listing rules, including minimum bid price and stockholder equity, while also addressing a change of control following an acquisition.

Summary

• Ensysce Biosciences received notification from Nasdaq on August 25, 2026, that it now complies with the $2.5 million stockholders equity requirement, but must evidence this in its next periodic report to avoid delisting.
• The company was previously notified on February 25, 2026, of non-compliance with the minimum bid price requirement (below $1.00) and has been granted an extension until February 22, 2027, to regain compliance.
• Following the acquisition of Cy Biopharma, Inc. on August 5, 2026, Nasdaq has classified this as a Change of Control, requiring the post-transaction company to satisfy initial listing criteria and complete the listing process before shareholder approval of preferred stock conversion.
• Failure to meet Nasdaq listing requirements could lead to a suspension of trading.
• The company intends to take necessary actions to regain compliance with all requirements and submit an initial listing application for the post-transaction entity.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to ongoing compliance issues with Nasdaq listing requirements, despite some recent positive steps.

Positives

• The company has regained compliance with the $2.5 million stockholders equity requirement as of August 25, 2026.
• Nasdaq has granted an additional 180-day extension, until February 22, 2027, to regain compliance with the minimum bid price requirement.

Negatives

• The company is still subject to delisting if it fails to evidence compliance with the stockholders equity requirement in its next periodic report.
• The company is at risk of delisting if it cannot meet the minimum bid price requirement by February 22, 2027.
• The acquisition of Cy Biopharma triggered a Change of Control notification from Nasdaq, necessitating a new initial listing process.
• Failure to meet Nasdaq listing requirements post-transaction will result in a suspension of trading.

Risks

• Risk of delisting from The Nasdaq Stock Market LLC if compliance with listing rules (stockholder equity and minimum bid price) is not demonstrated.
• Potential suspension of trading if the post-transaction company fails to satisfy Nasdaq's initial listing criteria.
• Uncertainty regarding the successful completion of the initial listing process for the combined entity post-acquisition.

Future Outlook

The company intends to take all necessary actions to regain compliance with Nasdaq's listing requirements, including submitting an initial listing application for the post-transaction entity, and believes it will be able to evidence compliance with the stockholders equity requirement in its next periodic report.

Management Comments

• The Company believes it will be able to evidence compliance with the stockholders equity requirement in its next periodic report.
• The Company intends to take actions necessary to regain compliance with the Minimum Price Listing Requirement.
• The Company intends to submit timely an initial listing application for the post-transaction company.

Industry Context

StockSavvy.ai notes that maintaining Nasdaq listing compliance is critical for biotechnology companies, especially those undergoing significant corporate events like acquisitions, as it directly impacts investor confidence and access to capital markets.

Stakeholder Impact

• Shareholders: Potential for increased volatility and risk of trading suspension if Nasdaq listing requirements are not met.
• Creditors: Potential impact on the company's ability to secure future financing if trading is suspended.
• Employees: Uncertainty regarding job security and company stability due to ongoing compliance issues.

Next Steps

• Evidence compliance with the $2.5 million stockholders equity requirement in the next periodic report.
• Regain compliance with the minimum bid price requirement by February 22, 2027.
• Satisfy Nasdaq's initial listing criteria for the post-transaction company.
• Complete the initial listing process for the post-transaction company.
• Obtain shareholder approval for the conversion of preferred stock issued in the Cy Transaction.

Key Dates

Recommendation

The company is navigating significant Nasdaq compliance challenges following an acquisition. While it has made progress on equity requirements and secured extensions for bid price, the need for a new listing process introduces substantial uncertainty. A 'hold' recommendation reflects the balance between potential recovery if compliance is achieved and the significant risks of delisting or trading suspension.

Keywords

Nasdaq compliance, delisting risk, minimum bid price, stockholder equity, Change of Control, Cy Biopharma acquisition, initial listing criteria, trading suspension